Cargando…

THU077 Differences In Clinicopathological Features Of Acidophil Stem Cell Adenomas Compared To Other Subtypes Of Acromegaly: A Retrospective Study

Disclosure: K.C. Yuen: Advisory Board Member; Self; Novo Nordisk, Ascendis, Corcept Therapeutics, Ipsen, Amryt, Strongbridge, Crinetics, Recordati, Xeris. Grant Recipient; Self; Corcept Therapeutics, Crinetics, Ascendis, Amryt. Speaker; Self; Corcept Therapeutics, Novo Nordisk, Recordati. E. Smith:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji Yuen, Kevin Choong, Smith, Elizabeth, Bernabe, Frank Cossio, Eschbacher, Jennifer M, Rodriguez, Monica, Little, Andrew S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Neuroendocrinology & Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555827/ http://dx.doi.org/10.1210/jendso/bvad114.1157

Ejemplares similares

THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023)

THU022 A Case Of Delayed Diagnosis Of Acromegaly
por: Blanchard, Kayla, et al.
Publicado: (2023)

THU065 Evaluation Of Sarcopenia And Bone Health In Patients With Acromegaly
por: Eroglu, Imdat, et al.
Publicado: (2023)

THU060 Time To First Remission, Medical Therapy And Survival In Acromegaly: UK Acromegaly Register (UKAR) Study
por: Deshmukh, Harshal, et al.
Publicado: (2023)

Pleurihormonal Pituitary Adenomas Presenting as Acromegaly
por: Schwehr, Megan, et al.
Publicado: (2021)

THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly
por: Falch, Camilla Maria, et al.
Publicado: (2023)

THU059 Increased Intracellular And Extracellular Myocardial Masses On Cardiac Magnetic Resonance Imaging In Patents With Acromegaly
por: Wolf, Peter, et al.
Publicado: (2023)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

THU071 Key Device Attributes For Injectable SRL Therapy In Acromegaly And NETs To Aid Clinical Decision Making
por: de Herder, Wouter W, et al.
Publicado: (2023)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

RF01 | PMON168 Hedgehog-Induced Somatostatin Receptor Expression is Inhibited by the Activation of the Glucocorticoid Receptor Signaling Pathway in Human Pituitary Adenoma Organoids
por: Zavros, Yana, et al.
Publicado: (2022)

THU068 Evaluation Of Nonalcoholic Fatty Liver Disease, Liver Fibrosis And Serum Angiopoietin-like Protein Levels In Patients With Acromegaly
por: Eroglu, Imdat, et al.
Publicado: (2023)

THU028 Novel Approach To Management Of Acromegaly With De Novo Oral Octreotide Or Combination Therapy With Cabergoline: A Case Series
por: Halstrom, Amanda, et al.
Publicado: (2023)

OR20-05 Generation Of CDH23-mutated Pituitary Neuroendocrine Tumor Organoids From Induced Pluripotent Stem Cells To Model Cushing’s Disease Pathogenesis
por: Chakrabarti, Jayati, et al.
Publicado: (2023)

SUN-LB077 Relationship between Responses from Acromegaly Patients Treated with a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice and Their Endocrinology Health Care Professional Regarding Treatment Outcomes: Preliminary Findings
por: Geer, Eliza, et al.
Publicado: (2019)

SAT-LB077 Remission and Mortality Rates in Patients with Cushing Disease According to Their Tumor Size
por: Lam-Chung, Cesar, et al.
Publicado: (2019)

THU008 Coverage Of Education And Training Of Traumatic Brain Injury-induced Growth Hormone Deficiency In US Endocrinology Fellowship Programs
por: Ji Yuen, Kevin Choong, et al.
Publicado: (2023)

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load
por: Godlewska, Magdalena, et al.
Publicado: (2023)

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023)

SAT625 The EGF-TBX19-EGFR Positive Feedback Loop Regulates The Expression Of The CD44v9/SLC7A11 Antioxidant System Within Corticotroph Pituitary Neuroendocrine Tumors
por: Chakrabarti, Jayati, et al.
Publicado: (2023)

THU023 Sparse Granulation In Growth Hormone Secreting Adenomas: Clinical Implications Of A Rare Histological Finding
por: Merrill, Andrew, et al.
Publicado: (2023)

LBODP077 The Therapeutic Potential Of Targeting Histone Deacetylase For Pituitary Neuroendocrine Tumors By High-throughout Drug Screening
por: Wu, Zhe Bao, et al.
Publicado: (2022)

SAT-259 Acromegaly by Pituitary Adenoma Associated with ACTH-Independent Cushing Syndrome by Adrenal Carcinoma: Case Report
por: Minuzzi, Ricardo Kunde, et al.
Publicado: (2020)

Differences in Menin Expression in Pituitary Adenomas in Multiple Endocrine Neoplasia Type 1, Its Phenocopies and Sporadic Acromegaly
por: Dimitrova, Diana A, et al.
Publicado: (2021)

THU089 Natural Course Of Non-Functioning Pituitary Adenoma According To Age And Sex: A Longitudinal Observational Study
por: Park, Seung Shin, et al.
Publicado: (2023)

THU010 A Case Of Cushing(')s Disease Due To T-pit Positive, ACTH Negative Aggressive Corticotroph Pituitary Adenoma
por: Gopinath, Chaitra, et al.
Publicado: (2023)

THU012 Incidental Pituitary Adenoma In A Patient With Ectopic ACTH Secreting Cushing Syndrome - A Diagnostic Conundrum
por: Nali, Meenakshi Sinduri, et al.
Publicado: (2023)

THU072 Association Between Nonalcoholic Fatty Liver Disease And Growth Hormone Deficiency In Patients With Nonfunctioning Pituitary Adenoma
por: Hwang, Yoon-a, et al.
Publicado: (2023)

MON-LB077 A Large Single Institution Series of Neuroendocrine Recovery and Tumor Recurrence after Pituitary Apoplexy
por: Brown, Teresa, et al.
Publicado: (2019)

FRI370 Hyperthyroidism And Acromegaly In A Patient With A Mature Plurihormonal PIT1 Lineage PitNET/Adenoma
por: Slack, Daniel, et al.
Publicado: (2023)

THU055 The Acro-TIME Score: A New Clinical, Pathological And Immune Integrative Approach To Early Identify Acromegaly Patients Resistant To Treatment With First Generation Somatostatin Ligands
por: Chiloiro, Sabrina, et al.
Publicado: (2023)

MON-440 Cyberknife Radiosurgery for Functional and Non-Functional Pituitary Adenomas: Long-Term Single-Center Experience
por: Yuen, Kevin, et al.
Publicado: (2019)

THU044 The Subcellular Localization Of β-Catenin Is Associated With Tumor Size And The Surgical Remission Rate In Growth Hormone-producing Pituitary Adenomas
por: Kuwabara, Saki, et al.
Publicado: (2023)

THU078 The Definition And Epidemiology Of Giant Pituitary GH-Secreting Adenomas Based On Clinical, Imaging, And Hormonal Parameters: A Pilot Study
por: Del Corso, Leticia Marinho, et al.
Publicado: (2023)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

SAT-468 Conversion of a Non-Secreting to a Growth Hormone-Secreting Pituitary Adenoma: A Case of Rapid Development of Acromegaly
por: Motwani, Komal, et al.
Publicado: (2019)

ODP320 Immune Organs Enlarged in Acromegaly: Evaluation of Thymus Volume in Patients with Acromegaly
por: Nahit Sendur, Suleyman, et al.
Publicado: (2022)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry
por: Geer, Eliza Brevoort, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bctc4dmdjop2m6rfge12qvi5iq